This article was originally published by Rhoda Wilson at The Daily Exposé.
Four days ago, The Guardian reported that there was “excitement among patients and researchers” in the UK as “personalized mRNA vaccines” for cancer entered their phase 3 trial. On Monday, In Your Area published an article about a personalized mRNA skin cancer vaccine that may also be effective against lung, bladder, and kidney cancer.
However, patients may be less excited about these “groundbreaking” injections when they read a paper published last week.
On 23 April, a pre-print paper (not yet peer-reviewed) was published in the journal Authorea that reviewed oncogenesis and autoimmunity caused by mRNA injections. It found that repeated mRNA injections reduce immune surveillance for cancer while at the same time inducing autoimmunity.
Further reading:
Oncogenesis or carcinogenesis is the process through which healthy cells become transformed into cancer cells.
Autoimmunity is an immune response resulting from a failure of our immune system to recognize our own cells and tissues as “self.”
The paper extensively reviewed the role of regulatory T cells (“Treg”) cells in the immune system, with a particular focus on the disruption of their behavior caused by the mRNA injections.
Treg cells modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells also suppress the immune response to cancer and have been shown to contribute to the development and progression of the disease.
The paper found that post-vaccination, the subsequent spike protein expression “may lead to a harmful influence on the immune system of vaccinees and subsequent accelerated development of cancer and autoimmune disease.”
Although the paper specifically reviewed these conditions relating to COVID-19 mRNA injections, the concerns raised in the paper apply to all mRNA injections.
“Sadly, Moderna among many mRNA companies has plans for mRNA cancer drugs. They have a long drug development pathway to prove mRNA will not cause more cancer than it intends to treat,” Dr. Peter McCullough says.
Oncogenesis and Autoimmunity as a Result of mRNA Covid-19 Vaccination
By Dr. Peter Mccullough
Every cancer registry in the world is up with new cases and documented rapid progression of disease aptly termed “turbo cancer.” The trendline went up with the rollout of genetic COVID-19 vaccines. What mechanism could explain an injection of Pfizer or Moderna mRNA and the genesis of cancer?
Kyriakopoulos et al have recently published a thorough investigation into the response by regulatory T-cells after encountering repeated injections of foreign mRNA.
An inappropriate homeostatic balance among T-effector, T-regulatory and memory T-regulatory cells can direct the immune system toward either cancer or autoimmunity. When cancer is present, Treg cells suppress anti-tumour immunity, and, when cancer is absent, Treg cells play the beneficial role of preventing the development of autoimmunity.
In this review, we analyse Treg responses after SARS-CoV-2 mRNA vaccination and find distinct pathological responses under differing conditions. In cancer patients, the degree of disease progression depends on the cancer status at the time of vaccination and the type of cancer treatment they receive concurrently. We hypothesise that migration of circulating dendritic cells and mTreg cells back to the thymus accelerates thymic involution, a direct cause of immunosenescence.
In summary, the Treg responses produced after mRNA vaccination and the subsequent mRNA-encoded SARS-CoV-2 spike protein expression may lead to a harmful influence on the immune system of vaccinees, and subsequent accelerated development of cancer and autoimmune disease. These mechanisms are consistent with both epidemiological findings and case reports.
In other words, repeated injections of mRNA COVID-19 vaccines are taking down immune surveillance for nascent malignant cells while at the same time inducing autoimmunity.
Skipping preclinical oncogenicity studies turned out to be a disaster for mRNA products. Concerns raised in this paper apply to any new mRNA product coding for a non-human or pathological protein target. Sadly, Moderna among many mRNA companies has plans for mRNA cancer drugs. They have a long drug development pathway to prove mRNA will not cause more cancer than it intends to treat.
About the Author
Dr. Peter McCullough is an internist and cardiologist in academic practice in Dallas, Texas, and the Chief Scientific Officer of The Wellness Company.
He has published papers on a range of topics in medicine with over 1,000 publications and 660 citations in the National Library of Medicine. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal, and other top-tier journals worldwide. He is the editor-in-chief of Reviews in Cardiovascular Medicine and senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals.
Together with John Leake, Dr. McCullough publishes articles on a Substack page titled ‘Courageous Discourse’ which you can subscribe to and follow HERE.
Read the full article here
